The appointment signals a focus on regulatory preparedness for zorevunersen. Traders should monitor for upcoming Phase 3 data readouts and potential regulatory milestones, which this addition to the board may help facilitate.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 8 $34.87entry
- T+1 · 7mo ago +0.80%α +0.23% · $35.15
- T+5 · 7mo ago +1.92%α −1.60% · $35.54
- T+20 · 7mo ago −5.48%α −14.02% · $32.96
- T+60 · 4mo ago −6.22%α −16.68% · $32.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stoke Therapeutics appointed Dr. Clare Kahn, a seasoned biotech executive with deep regulatory and drug development expertise, to its board of directors. The move strengthens governance ahead of key Phase 3 data readouts for its lead candidate, zorevunersen, in Dravet syndrome.
Key Facts
- Dr. G. Clare Kahn, Ph.D., was appointed to Stoke's Board of Directors effective April 3, 2026.
- Dr. Kahn brings over three decades of industry experience, including senior roles at Pfizer, GSK, and X-VAX Technology Inc., with expertise in rare disease drug development and regulatory strategy.
- She was also appointed chairperson of the Research and Development Committee and to the Nominating and Corporate Governance Committee.
- The board size was increased to ten directors to accommodate the appointment.
- Dr. Kahn received an initial stock option grant valued at approximately $724,000 and will receive an annual cash retainer of $45,000.
Financial Impact
Approximately $724,000 in initial stock option grant value and $45,000 annual cash retainer for Dr. Kahn's board service.
Risk Factors
- Biotech clinical-stage risk: The company's value is highly dependent on the success of zorevunersen, which is still in development.
- Dilution risk: The stock option grant, while standard for board appointments, represents a small degree of shareholder dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-145524 |
| Document: d63742dex991.htm | 0001193125-26-145524 |
| Document: 0001193125-26-145524-index-headers.html | 0001193125-26-145524 |
| Document: 0001193125-26-145524-index.html | 0001193125-26-145524 |
| Document: 0001193125-26-145524.txt | 0001193125-26-145524 |
Track record
18 reports on STOK
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.63 Now $26.63 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.84 Now $26.63 −0.78% settles Feb 12
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers